Abstract: Provided are deuterated analogs of MDMA, including deuterated empathogens. In some embodiments, such compounds are monoamine releasers or inhibit monoamine transporters. In some aspects, features of the compounds provide stability, such as metabolic stability, and efficacy. Also provided are methods for the preparation of deuterated empathogens and pharmaceutical compositions comprising the same. Methods of using the deuterated empathogens, alone or in combination with other therapeutic agents, are provided. In some embodiments, deuterated empathogens are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders.
Type:
Grant
Filed:
August 23, 2022
Date of Patent:
July 23, 2024
Assignee:
Alexander Shulgin Research Institute, Inc.
Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.
Type:
Grant
Filed:
March 21, 2022
Date of Patent:
July 16, 2024
Assignee:
THE PENN STATE RESEARCH FOUNDATION
Inventors:
Joshua E. Allen, Gen Sheng Wu, Wafik S. El-Deiry
Abstract: Provided are near-infrared nerve-sparing fluorescent compounds, compositions comprising them, and methods of their use in medical procedures.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
July 9, 2024
Assignee:
Oregon Health & Science University
Inventors:
Summer L. Gibbs, Lei G. Wang, Connor W. Barth
Abstract: The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
Type:
Grant
Filed:
November 16, 2021
Date of Patent:
June 25, 2024
Assignee:
DS Biopharma Limited
Inventors:
Mehar Manku, John Climax, David Coughlan
Abstract: The disclosure relates to compounds of formula (I): Among the substituents in a compound of formula (I), one of R4 and R5 is hydrogen and the other of R4 and R5 is —OSC2Rs6. The disclosure relates to compounds of formula (II): Among the substituents in a compound of formula (II), R6 is a halogen chosen from F, Cl, Br, and I. The disclosure relates to compositions comprising a compound of formulas (I) or (II) and an excipient. The disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulas (I) or (II). The disclosure relates to therapeutic uses of compounds of formulas (I) or (II).
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
June 25, 2024
Assignees:
Belite Bio, Inc, The Trustees of Columbia University in the City of New York
Inventors:
Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Konstantin Petrukhin
Abstract: Disclosed are systemic and intravaginal non-hormonal contraceptives comprising a spermicidal triterpenoid. The contraceptive may be in the form of a foam, cream or gel, or in unit form of a pill, vaginal contraceptive film (VCF), suppository, sponge, transdermal or hypodermal patches or a slow release intravaginal device or intrauterine device such as a drug-impregnated silicone elastomer vaginal ring or polymeric IUD.
Type:
Grant
Filed:
June 18, 2019
Date of Patent:
May 21, 2024
Assignee:
The Regents of the University of California
Abstract: Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.
Type:
Grant
Filed:
June 15, 2023
Date of Patent:
May 21, 2024
Assignee:
Vivasor, Inc.
Inventors:
Long Mao, Xiao Xu, Namir Shaabani, Can Jin
Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for the treatment of retinal binding protein (RBP4) related diseases, such as obesity and the like.
Type:
Grant
Filed:
April 12, 2021
Date of Patent:
May 14, 2024
Assignees:
Belite Bio, Inc, The Trustees of Columbia University in the City of New York
Inventors:
Yu-Hsin Tom Lin, Cheng-Chi Irene Wang, Konstantin Petrukhin
Abstract: The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R1, R2a, and R2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.
Type:
Grant
Filed:
August 8, 2022
Date of Patent:
May 7, 2024
Assignee:
Janssen Pharmaceutica NV
Inventors:
Bashkim Kadriu, John A. Moyer, Gahan J. Pandina, Ryan Michael Wyatt
Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Type:
Grant
Filed:
January 10, 2023
Date of Patent:
March 26, 2024
Assignees:
NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Type:
Grant
Filed:
January 10, 2023
Date of Patent:
March 26, 2024
Assignees:
NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Type:
Grant
Filed:
August 30, 2022
Date of Patent:
March 26, 2024
Assignees:
NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.
Type:
Grant
Filed:
January 10, 2023
Date of Patent:
March 26, 2024
Assignees:
NEUVIVO, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: A composition for promoting mitochondrial biogenesis includes an effective amount of an azelaic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Azelaic acid, which is a compound mainly contained in cereals and natural products has the advantage of no or little side effects, and induces mitochondrial autophagy and mitochondrial DNA synthesis in cells, thereby having activity of increasing mitochondrial density. Therefore, azelaic acid can be used for the treatment of mitochondrial dysfunction-associated disease caused by the failure of homeostasis control of the mitochondria, for example, mitochondrial activity or the decrease in the number of mitochondria.
Type:
Grant
Filed:
September 2, 2020
Date of Patent:
March 19, 2024
Assignee:
Korea University Research and Business Foundation
Abstract: Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
Type:
Grant
Filed:
September 16, 2022
Date of Patent:
March 19, 2024
Assignee:
Enveric Biosciences Canada Inc.
Inventors:
Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling